News from neuralstem, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 05, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment Conference

Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual Rodman & Renshaw Global...

Aug 08, 2014, 08:00 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and six months ended June 30, 2014 and provided a...

Aug 04, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural...

Jun 30, 2014, 09:15 ET

Neuralstem Added To Russell 3000 Index

 Neuralstem, Inc. (NYSE MKT: CUR) reports that its shares have been added to the broad-market Russell 3000® Index. Annual...

Jun 25, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder

 Neuralstem, Inc. (NYSE MKT: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were...

Jun 19, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress

 Neuralstem, Inc. (NYSE MKT: CUR) announced that select data from the NSI-189 Phase Ib trial in patients with major depressive disorder (MDD)...

Jun 18, 2014, 09:15 ET

Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting

 Neuralstem, Inc. (NYSE MKT: CUR)  announced that final data from the Neuralstem NSI-189 Phase Ib study in major depressive disorder (MDD)...

May 23, 2014, 09:28 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical Psychopharmacology Annual Meeting

 Neuralstem, Inc. (NYSE MKT: CUR) announced that data from the NSI-189 Phase Ib study in major depressive disorder (MDD) will be presented at...

May 16, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem CEO, Richard Garr, to Present at World Stem Cells & Regenerative Medicine Congress and Give Update on Trials

 Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress,...

May 12, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2014 and provided a business and...

May 08, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Appoints Sandford Drexel Smith, Former Genzyme Executive Vice President, To Board Of Directors

 Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Sandford Drexel Smith to its Board of Directors, bringing the total number of...

Apr 16, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego

Neuralstem, Inc. (NYSE MKT: CUR) announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has...

Apr 07, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference

 Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, PhD, MD, principal investigator of Neuralstem's NSI-566 stem cell...

Mar 28, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats

 Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats...

Mar 17, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the...

Mar 10, 2014, 09:00 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Announces 2013 Financial Results

 Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trials program and reported its 2013 financial results for...

Feb 06, 2014, 09:00 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem President and CEO to Present NSI-566 Clinical Trials Program Update at BIO CEO & Investor Conference 2014

Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual BIO CEO & Investor...

Jan 14, 2014, 09:00 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Appoints Catherine Angell Sohn To Board Of Directors

 Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board...

Jan 13, 2014, 15:50 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase

 Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the sixth annual Biotech Showcase...

Jan 13, 2014, 09:46 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

First Patient Treated In Neuralstem China Stem Cell Trial To Treat Stroke Motor Deficits

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor...